Intangible Assets (Narrative) (Details) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Aug. 14, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Aug. 23, 2021 |
|
| Finite-Lived Intangible Assets [Line Items] | ||||
| Impairment of intangible assets | $ 565,000 | |||
| Amortization of Intangible Assets | 126,000 | $ 401,000 | ||
| Patents and Licenses [Member] | ||||
| Finite-Lived Intangible Assets [Line Items] | ||||
| Impairment of intangible assets | $ 25,000 | 565,000 | $ 0 | |
| Amortization of Intangible Assets | $ 47,000 | |||
| Weighted average remaining life | 1 year 6 months | |||
| Intellectual Property [Member] | ||||
| Finite-Lived Intangible Assets [Line Items] | ||||
| Amortization of Intangible Assets | $ 79,000 | |||
| Weighted average remaining life | 19 years 3 months 18 days | |||
| RubrYc Therapeutics, Inc. [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | ||||
| Finite-Lived Intangible Assets [Line Items] | ||||
| Investment | $ 7,500,000 | |||